semaglutide hepatic impairment pharmacokinetics Phase 3 Trial of in Metabolic Dysfunction–Associated Steatohepatitis Pharmacokinetics, Safety, and Tolerability of

Different Mechanisms : Tirzepatide and Retatrutide work on different receptor pathways

Nature 464:5965

Choose Semaglutide If You have established cardiovascular disease (prior heart attack, stroke, stent, peripheral artery disease) You're over 50 with multiple cardiovascular risk factors (hypertension, high LDL, smoking history, family history) You've already lost most of the weight you want to lose and you're switching from short-term weight loss to long-term metabolic protection You want the longest-running real-world safety data on a GLP-1 Choose Tirzepatide If Your primary goal is maximum weight loss in the shortest timeframe You don't have established cardiovascular disease You've plateaued on semaglutide and need stronger appetite suppression You tolerate tirzepatide better (some people get less GI upset on dual agonism) What's Still Available After the FDA Crackdown 503A compounding pharmacies continue to prepare both peptides for documented medical need

Many people reported positive effects, such as reduced anxiety and depression symptoms, increased energy, clearer thinking, and better control over compulsive behaviors like smoking and shopping

Large amounts of foam mean peptide is trapped in air-liquid interfaces, reducing the actual concentration of your solution